BMI: Tom Brady is obese?

Your Body Mass Index (BMI) is a measurement of your body fat percentage. And based on the results, you are labeled normal, overweight or obese.   But BMI can give you some crazy results. Using this measurement, I’m considered obese. And so is NFL superstar Tom Brady. You see, BMI only compares your height against your weight. It doesn’t distinguish between fat and muscle. But here’s the thing… Muscle is much denser than fat. So if you have a lot of muscle, you can have a high BMI but still be lean. There’s a much more reliable test to measure your body’s composition of fat and muscle. It’s called dual-energy X-ray absorptiometry (DXA or DEXA). In my clinic, it’s one of the first tests I give to my patients. You probably know the DEXA test as the gold standard for measuring bone density. But new research shows it can also give you a detailed snapshot of your body’s composition of bone, muscle and fat.   In a recent study of 50 women, doctors compared BMI with DEXA results. They found that some women who were told they were overweight based on their BMI actually had normal fat levels on their DEXA.1 And 18.5% of the women with normal BMI actually had a lot of excess fat based on their DEXA. In other words, they were “skinny fat” people. You see, the BMI also can’t measure deadly visceral fat. This type of fat collects in your abdominal cavity. It surrounds your organs and restricts them. Vis...
Source: Al Sears, MD Natural Remedies - Category: Complementary Medicine Authors: Tags: Anti-Aging Source Type: news

Related Links:

During her career, Debbie DiCarlo had worked for nonprofits dealing with immigration, foster case, sex trafficking and domestic violence, but she never saw herself working for a cancer organization. That is, until her best friend was diagnosed with cancer, and she subsequently moved to the Valley from California to do just that.
Source: Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Mississippi health officials have issued an advisory that COVID-19 vaccines are safe, effective and recommended to pregnant women after reports some were turned away at clinics.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Shares of a Bay Area biotech company shot up more than 157% and another climbed to a lesser degree Friday after a Big Pharma company reported that a cancer drug with a shared target appeared effective in fighting tumors. Both Corvus Pharmaceuticals Inc. (Nasdaq: CRVS) of Burlingame and Arcus Biosciences Inc. (NYSE: RCUS) of Hayward shot up after AstraZeneca plc reported fresh data from a mid-stage clinical trial. That Big Pharma player said its already-approved cancer immunotherapy Imfinzi showed…
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Koios Medical recently entered into a strategic partnership with GE Healthcar...Read more on AuntMinnie.comRelated Reading: AI can help classify masses found on breast ultrasound Koios secures FDA breakthrough designation for breast AI Koios Medical's AI for detecting breast cancer gets CE Mark Koios touts study on AI for breast biopsy FDA clears Koios Medical's breast cancer software
Source: Headlines - Category: Radiology Source Type: news
This study aims to explore the effect of the ITI (interferon alpha-1b, thalidomide, and interleukin-2) regimen on the AML1-ETO fusion gene in patients with t(8;21) acute myeloid leukemia (AML) who were in hematologic remission but positive for the AML1-ETO fusion gene. From September 2014 to November 2020; 20 patients with AML (15 from The Affiliated Cancer Hospital of Zhengzhou University, 4 from The First Affiliated Hospital; and College of Clinical Medicine of Henan University of Science and Technology, and 1 from Anyang District Hospital) with hematological remission but AML1-ETO fusion gene positivity were treated wit...
Source: Annals of Hematology - Category: Hematology Source Type: research
AbstractWe investigated the feasibility and activity of an intensified dose-dense ABVD (dd-ABVD) regimen in patients with early-stage unfavorable Hodgkin lymphoma (HL). This prospective, multicenter, phase II study enrolled 96 patients with newly diagnosed, unfavorable stage I or II classical HL. The patients received four cycles of dd-ABVD followed by radiotherapy. Interim PET (PET-2) was mandatory after two courses. Primary endpoints were the evaluation of dd-ABVD feasibility and activity (incidence of PET-2 negativity). The feasibility endpoint was achieved with 48/52 (92.3%) patients receiving  >  85% ...
Source: Annals of Hematology - Category: Hematology Source Type: research
AbstractAcute myeloid leukemia (AML) relapse after allogeneic stem cell transplant (alloSCT) remains a major therapeutic challenge. While patients with longer remission after initial alloSCT are recommended to receive cell therapy (CT) such as 2ndalloSCT or donor lymphocyte infusion (DLI), survival for patients who relapse within 6  months of alloSCT has been dismal. We evaluated the outcomes of AML relapse after alloSCT to assess the impact of different treatments on long-term survival. One hundred and seventy-two patients with AML underwent alloSCT at the Penn State Cancer Institute from January 2014 to August 2019....
Source: Annals of Hematology - Category: Hematology Source Type: research
The same advisers overwhelmingly recommended against authorizing boosters for people under 65, complicating the Biden administration ’s hopes to offer them more broadly.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Vaccination and Immunization Coronavirus (2019-nCoV) Food and Drug Administration Pfizer Inc BioNTech SE United States Source Type: news
Maunil K. Desai1 and Roberta Diaz Brinton2,3* 1School of Pharmacy, University of Southern California, Los Angeles, CA, United States 2Center for Innovation in Brain Science, University of Arizona, Tucson, AZ, United States 3Departments of Pharmacology and Neurology, College of Medicine, University of Arizona, Tucson, AZ, United States Women have a higher incidence and prevalence of autoimmune diseases than men, and 85% or more patients of multiple autoimmune diseases are female. Women undergo sweeping endocrinological changes at least twice during their lifetime, puberty and menopause, with many women undergoin...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Complementary Medicine | DEXA Scan | Diabetes | Diets | Eating Disorders & Weight Management | Endocrinology | Heart | Heart Disease | Insurance | Insurers | Liver | Mammography | Men | Menopause | Nutrition | Obesity | Orthopaedics | PET Scan | Pregnancy | Skin | Sports Medicine | Study | Urology & Nephrology | USA Health | Women